144 Investor presentation First six months of 2023 Solid sales growth driven by Diab DKK billion Reported annual sales 2018-2022 16% 84% 16% +12% 1 15% 14% 86% 84% 85% 12% 88% 2018 2019 2020 2021 2022 Rare disease Diabetes and Obesity care 1 CAGR for 5-year period S&D: Sales and distribution; R&D: Research and development Note: The outlined expected developments are aspirations and not long-term financial targets
Download PDF file